Prescient Therapeutics ASX:PTX Boosts Oncology Pipeline | All Ordinaries

Highlights

• Prescient Therapeutics launches Share Purchase Plan to fund PTX-100 Phase 2 development

• Funds to support regulatory advancement of first-in-class GGT-1 inhibitor

• PTX-100 holds Orphan Drug and Fast Track designations from the US FDA

Prescient Therapeutics Ltd (ASX:PTX) has initiated a Share Purchase Plan (SPP) to support the continued development of its lead oncology therapy, PTX-100. The company, which forms part of the All Ordinaries index, is aiming to progress Phase 2 studies of the compound, a first-in-class inhibitor of geranylgeranyl transferase-1.

The SPP is open to eligible shareholders, with applications accepted until mid-July. Funds raised through the initiative are allocated primarily to clinical development and regulatory activities for PTX-100, aimed at treating cutaneous T-cell lymphoma (CTCL).

PTX-100 Development Enters New Phase

PTX-100 is a targeted therapy that interferes with the Ras signaling pathway, widely associated with cancer cell survival. The compound is currently undergoing a Phase 2A clinical trial in patients with relapsed or refractory CTCL. This follows a previous Phase 1B study that reported encouraging outcomes, which led to the initiation of further trials.

PTX-100 is Prescient’s most advanced candidate, and its development is supported by its designation as both an Orphan Drug and a Fast Track therapy by the US Food and Drug Administration. The trial has already begun dosing, marking a significant milestone in the company's oncology program.

Broad Pipeline Includes Modular and Immune-Enhancing Technologies

Alongside PTX-100, Prescient Therapeutics is also advancing a suite of technologies designed to improve cancer immunotherapies. These include:

• CellPryme-M & CellPryme-A: Tools developed to enhance the effectiveness of T-cell therapies by modulating the tumour microenvironment.

• OmniCAR: A modular CAR-T cell therapy platform that allows for more precise and controlled treatment of various cancers, currently in preclinical stages.

SPP Participation Details and Management

Eligible shareholders have the option to apply through BPAY or by submitting a completed application form. The offer allows for applications of new shares priced at a discount, with full terms outlined in the upcoming SPP Offer Booklet.

The SPP is being managed by Reach Markets Pty Ltd, which will support shareholder queries throughout the process. Funds raised are intended to accelerate the PTX-100 program and expand Prescient’s clinical footprint in targeted oncology.